←
David Connell4,351 posts
David Connell avatar

David Connell

@drdavidc

Respiratory @NHSTayside | Hon Sen Lect @dundeeuni | Complex Lung Infections | Co-Chair Scottish TB Network | Own opinions

◷ Joined December 2010▧ 135 Photos and videos
NEJM avatar
⟳ David Connell retweeted
NEJM@NEJM·Nov 15

Zhang and colleagues report autoantibodies neutralizing interferon-α, -ω, and -β in a man who died from H7N7 influenza and mutations in the viral proteins that may facilitate adaptation to humans. Read the full report: nej.md/4iJ84CN

Post attachment
The Lancet avatar
⟳ David Connell retweeted
The Lancet@TheLancet·Nov 11

The 2022 Lancet COPD Commission called for a shift in thinking about COPD from an end-stage disease to one with different types of risk factors and trajectories. A new update reviews progress made in the take-up of the recommendations: spkl.io/60107wF4I

Post attachment
Dr.Mukesh , MD , DM avatar
⟳ David Connell retweeted
Dr.Mukesh , MD , DM@dr_immuno29·Nov 8

Multiple autoimmune labels. Could one immune defect connect them? High-yield pearls from #ACR26: WHEN TO SUSPECT Early onset • multiorgan autoimmunity • refractory disease • enteropathy • lymphoproliferation • recurrent infections. ADULTS COUNT ~25% of IEI patients first develop symptoms in adulthood. Autoimmunity may be the only clue; absent infections or family history does not exclude IEI. RECOGNISE THE PATTERN → RECONSIDER THE DIAGNOSIS • Sicca/nephritis + infections → APDS • Autoimmunity + cytopenias/enteropathy → CTLA4/LRBA • Arthritis + ILD/alveolar haemorrhage → COPA • Behçet-like disease → HA20 or STAT1 GOF GENETICS CAN REDIRECT THERAPY APDS → leniolisib CTLA4/LRBA → abatacept STAT1 GOF → consider JAK inhibition TEST BEYOND SMALL PANELS Consider exome/genome + copy-number analysis; reanalyse negative results. Suspected somatic variants need adequate sequencing depth. The next breakthrough may be a molecular diagnosis. Credit: Prof Megan A. Cooper #ACR26 #ACRambassador #Rheumatology #ClinicalImmunology #PrecisionMedicine

Post attachmentPost attachmentPost attachmentPost attachment
NEJM avatar
⟳ David Connell retweeted
NEJM@NEJM·Nov 3

In two replicate phase 3 trials involving patients with COPD who were receiving inhaled maintenance therapy, add-on tozorakimab resulted in a lower rate of moderate or severe exacerbations than placebo. Full results of the OBERON and TITANIA trials and Research Summary: nej.md/4zNqtWJ

Post attachment
Paul Sax avatar
⟳ David Connell retweeted
Paul Sax@PaulSaxMD·Nov 3

Terrific series of comments arguing against the use of RIF in MAC pulmonary disease. Thank you, @adil_rashidk

Several lines of evidence make a stong case *aganist* using Rif in MAC-PD: 1) Rif MICs aganist M avium remain far above current breakpoints for S aureus /MTB (0.06/0.5 mg/L); Median MIC being around 4 mg/L .....(1/n)

Jose Ramos Vivas avatar
⟳ David Connell retweeted
Jose Ramos Vivas@joseramosvivas·Oct 13

🧫🟢 ¿Por qué un hongo puede ser "susceptible" en el laboratorio 🔬, pero el paciente no mejora? 🏥🤔 📖 The Lancet Infectious Diseases explica por qué la concentración mínima inhibitoria (CMI) no predice por sí sola la respuesta clínica. #Micología #Antifúngicos 🍄🧬 La respuesta depende de múltiples factores: 🔬 Especie fúngica 💊 Exposición al antifúngico 📍 Foco de infección 🦠 Biopelículas y persistencia 🛡️ Inmunidad del paciente 📊 Los autores proponen un algoritmo para investigar las discrepancias entre laboratorio y evolución clínica. 🩺🔍 ¿Qué hacer? ✅ Integrar datos clínicos y farmacocinéticos. 💊 Monitorizar el antifúngico cuando esté indicado. 🎯 Controlar el foco infeccioso. 💡 👇🏻 doi.org/10.1016/S1473-3099(2… #Microbiología #InfeccionesFúngicas @SEMicrobiologia

Post attachment
Hayoung Choi avatar
⟳ David Connell retweeted
Hayoung Choi@hayoungcc·Oct 8

📢Happy to share an editorial, just published in @ThoraxBMJ, on a post hoc analysis of the CLEAR trial (PMID: 42557060)! To test or not to test: reassessing the need for drug response assessment before inhaled hypertonic saline thorax.bmj.com/content/early…

IDSA avatar
⟳ David Connell retweeted
IDSA@IDSAInfo·Jul 2

New #IDSAGuidelines! IDSA has released updated evidence-based recommendations on the prevention of invasive aspergillosis in adult solid organ transplant recipients: bit.ly/4whe7Dx

Post attachment
ERS publications avatar
⟳ David Connell retweeted
ERS publications@ERSpublications·Sep 27

ERJ Open Research: Treatment of patients with bronchiectasis with hypertonic saline or carbocisteine does not significantly reduce sputum viscoelastic properties and biomarker levels or alter bacterial community composition bit.ly/4r2X2KA

Post attachment
ATS Blue Journal avatar
⟳ David Connell retweeted
ATS Blue Journal@ATSBlueEditor·Sep 20

Airway mucus plugs in asthma and #COPD: pathobiology, imaging, and implications for clinical trials doi.org/10.1093/ajrccm/aamag… @atscommunity

ERS publications avatar
⟳ David Connell retweeted
ERS publications@ERSpublications·Sep 24

ERJ Open Research: CPA/ABPA overlap represents a distinct clinical phenotype in individuals with CPA associated with underlying airway disease, antifungal resistance and Th2-driven inflammation, with rising biomarkers linked to disease progression bit.ly/4eR5Xwv

Post attachment
ERS publications avatar
⟳ David Connell retweeted
ERS publications@ERSpublications·Sep 23

Breathe: Structural sequelae after TB underpin infectious PTLD: bacterial, fungal and non-TB mycobacterial. Complications are frequent yet under-diagnosed, worsening mortality and quality of life. bit.ly/4viER5M

Post attachment